|
New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children
PR Newswire UK (press release) ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today presented new data from the GRAZAX® Asthma Prevention (GAP) trial with GRAZAX®, ALK's allergy immunotherapy tablet against grass pollen allergy. The data, presented at the 2016 Annual Congress … |
View full post on asthma – Google News